Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
AUROPHARMA
Mr. Kambam Nithyananda Reddy · Hyderabad, India
₹1,590.70
▲+2.68%Auropharma is trading near its 52-week high with positive momentum, supported by consistent revenue growth and a buy analyst consensus, though its premium valuation requires careful monitoring.
Exchange
NSI
Currency
INR
Day range
₹1,554.40 – ₹1,598.70
52-week range
₹1,016.10 – ₹1,636.80
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears fairly valued at current levels given its premium P/E ratio of 26.4, trading in the upper third of its 52-week range, reflecting market optimism about its growth prospects.
2.8% below the 1-year high · trend up
Hedge-fund memo
Today
The stock is up 2.68% today, trading near its 52-week high with strong volume, indicating positive sentiment.
This week
Continued upward trend with the stock maintaining levels above its recent moving averages.
This month
The stock has shown consistent performance, gaining approximately 8-10% over the past month, outperforming the broader market.
Bull thesis
Bear thesis
News & sentiment
Neutral
2 headlines · 2 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).
15.86 vs 16.31211
-2.77% surprise
16.4344 vs 15.88534
3.46% surprise
14.61 vs 15.24155
-4.14% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| AUROPHARMA | 915.25B | 26.40 | 9.93% | 14.94% | 5.60% |
| LUPIN | 1.12T | 21.02 | 26.91% | 24.22% | 31.90% |
| GLENMARK | 638.25B | 46.85 | 14.07% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory hurdles in key markets like US and Europe
Mitigation: Diversification across multiple markets and strengthening compliance processes
Intense competition in generic formulations
Mitigation: Focus on higher-value specialty products and complex generics
Business intelligence
Competitive moat
Auropharma's competitive moat stems from its strong R&D capabilities, diversified product portfolio across regulated and emerging markets, and established manufacturing infrastructure.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Launch of new generic products in US market
Expansion of specialty formulations portfolio
Thesis builder
Bull case
Auropharma continues to gain market share in generic formulations and specialty segments, supported by strong R&D and strategic acquisitions.
Base case
The company maintains steady growth in its domestic market while expanding its international footprint, particularly in regulated markets.
Bear case
Increased competition in generic markets and pricing pressure in key geographies could pressure margins and growth.
Time horizon
12-24 months
Est. CAGR
8-12%
Entry (qual.)
Consider accumulating on dips toward 1400-1500 INR range
Exit (qual.)
Scale down if the stock approaches 1800 INR without corresponding earnings growth
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how AUROPHARMA fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain AUROPHARMA for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Accumulate at current levels for long-term growth, but monitor valuation and US market developments.
equitypandit.com·5d ago·weekly outlook vague
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
14.2 vs 16.49044
-13.89% surprise
| 16.30% |
| 14.30% |
| BIOCON | 701.96B | 153.42 | 1.15% | 15.56% | 2.30% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,554.40
Resistance (day/52w high)
₹1,598.70
Volume
10,31,767
Trend
up
RSI (14)
51
MACD
bearish
MA cross
golden
50-day MA
₹1,508.13
200-day MA
₹1,311.71
vs 200-DMA
21.3%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.